share_log
Moomoo 24/7 ·  04/11 08:05

Harmony Biosciences Announces Exclusive Agreement to Develop and Commercialize Tpm-1116, a Highly Potent and Selective Oral Orexin-2 Receptor Agonist

Harmony Biosciences宣佈簽訂獨家協議,開發和商業化Tpm-1116,一種高效的選擇性口服Orexin-2受體激動劑

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論